Dear Reader,
This year has been somewhat unexpected to say the least.
Due to the presence and effects of the COVID-19 virus, the year 2020 will be remembered in infamy. For no global event in recent times, has introduced this much disruption, despair and mayhem into the lives of every global citizen and commercial organisation worldwide. Such has been the impact of this pandemic, it has brought with it a sense of reflection and analysis to our lives, be it personal or professional, and this sentiment extends to businesses too be they a large established corporation or a fledgling start-up. This annual report, a feature we hope to adopt and continue going forward, allows for us to assess and take stock of the year and, in doing so, Nnadi’s Healthcare & Pharmaceuticals is not exempt from participating in this reflective behavior.
The year 2020 for Nnadi’s Healthcare & Pharmaceuticals was meant to be a year of growth through the presentation of ideas and the demonstration of our potential. As a result of this year’s events, 2020 has been a year of frustration, reorganisation and preparation. Nevertheless, in spite of this pandemic, we can take away positives that depict key milestones we’ve achieved this year.
Firstly, by the end of the first week in 2020, Nnadi’s Healthcare & Pharmaceuticals had finally revised and refined its initial business plan and in doing so, better articulated its vision, strategy and products- and how best these said products integrate into the ecosystem we seek to create in the years to come. This revised blueprint for Nnadi’s Healthcare & Pharmaceuticals, not only allows us to compete commercially, but also allows us to do so with a distinctive identity that is firmly in alignment with the company’s mission statement and values. Secondly, following the articulation of our blueprint, we were able to persuade an investor to provide the necessary capital required, whilst retaining 100% equity of the company in the process, to set our ambitions and goals into motion for the year ahead. Our third and final achievement of 2020, resides in registering and successfully securing the necessary intellectual property (IP) rights at this early stage. These rights do not only confer protection and credibility to both the company and our respective products, but will undoubtedly help us in navigating our way towards forging commercial partnerships and securing favourable deals, whilst consolidating our presence through the course of trade.
In fulfilling the above achievements, in the face of the most difficult year since our formation, we have laid the foundations upon which we can build a pharmaceutical company ready for the 21st Century.
As we head into 2021, there are again specific milestones we seek to meet that are essential to the long-term growth and expansion of Nnadi’s Healthcare & Pharmaceuticals. Firstly, we seek to successfully raise additional capital in another round of funding to continue sustained growth through this decade. Secondly, we aim to cover more ground in further advancing our product development intentions with regards to our OTC product category. We aim, before the end of 2021, to have achieved this milestone by landscaping a defined, detailed, yet flexible, route for our proposed drug candidate onto the UK market with preclinical testing commencing before the start of Q4 in 2021. Finally, we will strive to apply greater effort towards organically expanding our audience and reach through our website, social media channels and through the launch and sales of our maiden product Fergie’s Sparkling Water®.
We are not confined to these achievements, we are by no means limited to meeting these milestones to only then fall prey to complacency. These milestones are the minimum we hope to accomplish in 2021. Our aspirations for 2021, substantiated by our defined strategic plan, entails a year boasting achievements and attributes as, opposed to disruption and detraction. A year that sees us gradually, yet confidently, marching onwards towards our objectives, which should give rise to a successful year.
If there is one thing we have learnt as a business in 2020, it is how to deal with challenges that result in disappointment and delays. We have learnt to resolve such issues not only by way of proffering and implementing pragmatic solutions, but by having the discipline and clarity of mind to begin solving such difficulties soon after they presents themselves with unnerving alacrity. This is something that must not be overlooked and I am glad it is something I have come to appreciate this year.
In 2021, we foresee potential challenges that await us in the form of continued disruption of the COVID-19 virus heading into Q1 of 2021, a recovering UK economy from regional and national lockdowns and Brexit. I for one believe that we can overcome these challenges if they are presented before us in the upcoming year.
Aside from the acquired experience, determination and commitment that resides in this company, I believe that successfully securing the correct investors for Nnadi’s Healthcare & Pharmaceuticals will allow us to surmount a majority, if not all, obstacles in 2021. We seek an investor who acknowledges that the field of science, as well as an investment in science, is not for the faint-hearted. Therefore, we seek investors who are not only courageous, but also share our vision and confidence in the £70bn UK life science sector. A sector that is not only a key strategic sector with a rich historical heritage and global pedigree, but a crucible of ingenuity and innovation that helps put the UK’s best foot forward in a new post-Brexit era.
These are the expectations of Nnadi’s Healthcare & Pharmaceuticals entering into 2021 and I am confident that with our ambition, imagination and robustness, 2021 should be a prosperous year for us.
I would like to wish you and yours a Merry Christmas and a truly happy and prosperous New Year.
Most Sincerely,
Sonny Ume
Founder & Managing Director
Nnadi’s Healthcare & Pharmaceuticals